1-10 of 10
Alma Rodriguez, M.D.
Close
Sort by
Journal Articles

Double Hit Lymphoma: M.D. Anderson Experience

Yasuhiro Oki, MD, Mansoor Noorani, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Alma Rodriguez, M.D., Fredrick B Hagemeister, MD, Nathan Fowler, MD, Michael Wang, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Bouthaina S. Dabaja, MD, Chelsea Pinnix, M.D., Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Issa Khouri, MD, Jason R. Westin, MD, Luis E Fayad
Journal: Blood
Blood (2013) 122 (21): 1776.
https://doi.org/10.1182/blood.V122.21.1776.1776
Published: 2013
Journal Articles

Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay

Yasuhiro Oki, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Larry W. Kwak, MD, PhD, Luis E Fayad, Alma Rodriguez, M.D., Michael Wallace, MD, Victoria Carlton, PhD, Katherine Kong, Malek Faham, MD, PhD, Anas Younes, MD
Journal: Blood
Blood (2013) 122 (21): 627.
https://doi.org/10.1182/blood.V122.21.627.627
Published: 2013
Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD
Journal: Blood
Blood (2009) 114 (22): 3922.
https://doi.org/10.1182/blood.V114.22.3922.3922
Published: 2009
Journal Articles

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Vince D. Cataldo, M.D., Michael A. Thompson, M.D., PhD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, B. Nebiyou Bekele, PhD, Camilo Jimenez, M.D., William A. Murphy, M.D., Auris O. Huen, Pharm.D., Rebecca B. Arbuckle, Pharm.D., Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Nathan Fowler, M.D., Larry W. Kwak, M.D., Peter W. McLaughlin, M.D., Sattva S. Neelapu, M.D., Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, M.D., Fredrick B. Hagemeister, M.D.
Journal: Blood
Blood (2008) 112 (11): 5297.
https://doi.org/10.1182/blood.V112.11.5297.5297
Published: 2008
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 835.
https://doi.org/10.1182/blood.V112.11.835.835
Published: 2008
Journal Articles

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Amin M. Alousi, MD, Chitra Hosing, M.D., Rima M. Saliba, PhD., Rosamar B. Valverde, BSN, Farzaneh Maadani, BS, Martin Korbling, M.D., Grace J. Okoroji, MS, Luis E. Fayad, M.D., Anne M. Stachowiak, BS, William D. Erwin, MS, Paolo Anderlini, M.D., Marcos J. de Lima, M.D., Sergio A. Giralt, M.D., Uday R. Popat, M.D., Partow Kebriaei, M.D., Naoto T. Ueno, M.D., Peter W. McLaughlin, M.D., Barbara Pro, M.D., Michael Wang, M.D., Alma Rodriguez, M.D., Fredrick B. Hagemeister, M.D., Homer A. Macapinlac, M.D., Donald A. Podoloff, M.D., Richard E. Champlin, M.D., Issa F. Khouri, M.D.
Journal: Blood
Blood (2007) 110 (11): 620.
https://doi.org/10.1182/blood.V110.11.620.620
Published: 2007
Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2006) 108 (11): 2749.
https://doi.org/10.1182/blood.V108.11.2749.2749
Published: 2006
Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Gerald S. Falchook, MD, Richard Champlin, M.D., F.B. Hagemeister, M.D., Chitra Hosing, M.D., Larry W. Kwak, M.D., Susan O’Brien, M.D, Maria Alma Rodriguez, M.D., Srdan Verstovsek, M.D., Barbara Pro, M.D.
Journal: Blood
Blood (2006) 108 (11): 2460.
https://doi.org/10.1182/blood.V108.11.2460.2460
Published: 2006
Journal Articles

Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study.

Maria Alma Rodriguez, M.D., Andreas Sarris, M.D., Nam H. Dang, M.D., Luis Fayad, M.D., Andre Goy, M.D., Fredrick Hagemeister, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Felipe Samaniego, M.D., Anas Younes, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2004) 104 (11): 4602.
https://doi.org/10.1182/blood.V104.11.4602.4602
Published: 2004
Journal Articles

Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma (NHL): Subgroup Analyses.

Maria Alma Rodriguez, M.D., Jane N. Winter, M.D.
Journal: Blood
Blood (2004) 104 (11): 2488.
https://doi.org/10.1182/blood.V104.11.2488.2488
Published: 2004